Replies to post #370157 on Amarin Corp Plc (AMRN)

[Whalatane]

I’m only following MITIGATE because it’s using Vascepa and it’s an independent trial run by Kaiser ( I’m a CAD Kaiser patient )

The advantage of this trial is that it’s all “ in house “
Kaiser has a state of the art electronic tracking system
Roughly 40% of the Kaiser ASCVD patients they have asked to participate have signed on . That is a high number for clinical trials
This trial is well funded with a dedicated team monitoring compliance with the drug ( Vascepa ) being taken and collecting and analyzing the data .

THIS trial will tell us if Vascepa reduces the risk of hospitalization from Covid AND … in 2023 … if Vascepa reduces the risk of CV events in prior event patients … ie will it confirm R-IT risk reduction numbers for these subgroups via divergence of trial arms ( no V vs V ) after 1-2 yrs

Kiwi

[north40000]

The Toronto based trial with Bhatt et al is nearly/entirely complete. The Argentina or S. America trial I’ve lost track of—Bhatt was also involved in its design.

Thanks kiwi for filling in on Mitigate.